A Newly Approved Treatment for Childhood Blood Cancer
A targeted therapy previously approved for adults is now available for certain pediatric patients with blood cancer. The U.S....
A targeted therapy previously approved for adults is now available for certain pediatric patients with blood cancer. The U.S....
The FDA approved an oral combination of an epigenetic therapy along with an enzyme inhibitor to treat certain adults...
The FDA approved a molecularly targeted therapeutic to treat certain pediatric patients and young adults with anaplastic large-cell lymphoma, a rare form...
The FDA approved the first once-a-day pill to lower the levels of testosterone in certain patients with prostate cancer....
The FDA granted accelerated approval to a CAR T-cell therapy for certain adult patients with follicular lymphoma, a common...
The FDA granted accelerated approval to selpercatinib to treat solid tumors harboring RET gene fusions. The U.S. Food and...
The FDA has approved a CAR T-cell immunotherapy to treat certain adult patients with mantle cell lymphoma. The U.S....
The FDA approved an analog of a marine compound to treat certain patients with small cell lung cancer. The...
The FDA has granted accelerated approval to a molecularly targeted therapeutic along with a companion diagnostic to treat certain...
Tarlatamab-dlle is the first bispecific T-cell engager approved to treat a solid tumor. The U.S. Food and Drug Administration (FDA)...
The U.S. FDA granted accelerated approval to an immunotherapeutic and a companion diagnostic test to treat certain cancer patients...
The FDA approved encorafenib with binimetinib as a treatment for certain patients with non-small cell lung cancer. The U.S....
The FDA has approved pirtobrutinib for patients with heavily pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The U.S....
The CAR T-cell therapy is now approved for some patients with relapsed/refractory mantle cell lymphoma. The U.S. Food and...
The FDA has approved eflornithine to prevent relapse after standard-of-care therapy for neuroblastoma. The U.S. Food and Drug Administration...
The FDA approved zanubrutinib, a tyrosine kinase inhibitor, for this form of non-Hodgkin lymphoma. The U.S. Food and Drug...
The FDA approved the PD-L1 inhibitor atezolizumab to treat alveolar soft part sarcoma The U.S. Food and Drug Administration...
Tisotumab vedotin-tftv is approved to treat certain recurrent or metastatic cervical cancers. The U.S. Food and Drug Administration (FDA)...
The RET inhibitor is now fully approved to treat certain patients with RET fusion-positive thyroid cancers. The U.S. Food...
The FDA has approved an immunotherapeutic in combination with chemotherapy to treat certain patients with gastric cancer, gastroesophageal junction...
Certain patients with advanced multiple myeloma may be eligible for treatment with a new immunotherapy drug. The U.S. Food...
The FDA has approved the monoclonal antibody retifanlimab-dlwr for some patients with Merkel cell carcinoma. The U.S. Food and...
The FDA has approved another T-cell engager therapy for patients with heavily pretreated multiple myeloma The U.S. Food and...
The FDA granted accelerated approval to a new targeted therapy for certain patients with advanced or metastatic cholangiocarcinoma. The...
This is the first modified, donor cord blood–based stem cell therapy approved to reduce time to hematopoietic recovery and...
The FDA approved a kit that allows for liver-directed delivery of the chemotherapy melphalan to treat metastatic liver disease...
The U.S. FDA has approved a molecularly targeted therapeutic to treat patients with advanced systemic mastocytosis. The U.S. Food...
The FDA approved the targeted immunotherapy tebentafusp-tebn for certain adult patients with uveal melanoma. The U.S. Food and Drug...
The FDA approved the bispecific T-cell engager blinatumomab for use in the consolidation phase of therapy for certain patients...
THE FDA GRANTED ACCELERATED APPROVAL TO ZANUBRUTINIB FOR CERTAIN ADULTS WITH MARGINAL ZONE LYMPHOMA The U.S. Food and Drug...